Treatment of mice with the GR antagonist RU486 reversed the decreased allergic immune response induced by BPA leading to an eosinophilic airway inflammation, AHR and OVA-specific IgE levels comparable to OVA-sensitized control mice (Fig. 5A–D). The gene discussed is NR3C1; the disease is inflammatory response.